Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking

Journal of Medicinal Chemistry

Volumn 46, Issue 13, 2003, Pages 2656-2662

  Vangrevelinghe, Eric ^a   Zimmermann, Kaspar ^a   Schoepfer, Joseph ^a   Portmann, Robert ^a   Fabbro, Doriano ^a   Furet, Pascal ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

(5 OXO 5,6 DIHYDROINDOLO[1,2 A]QUINAZOLIN 7 YL)ACETIC ACID; 1,4 DIAMINO 5,8 DIHYDROXYANTHRAQUINONE; 4,5,6,7 TETRABROMO 1H BENZOTRIAZOLE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; PROTEIN KINASE 2 INHIBITOR; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; COMPUTER ANALYSIS; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HIGH THROUGHPUT DOCKING; IC 50; MOLECULAR MODEL; SEQUENCE HOMOLOGY;

ACETIC ACIDS; AMINO ACID SEQUENCE; BINDING SITES; CASEIN KINASE II; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP; ZEA MAYS;

EID: 0038792292     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030827e     Document Type: Article

References (44)

1. Pinna, L. A. Protein kinase CK2: a challenge to canons. J. Cell Sci. 2002, 115, 3873-3878.
2. Litchfield, D. W. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem. J. 2003, 369, 1-15.
3. Ahmed, K.; Gerber, D. A.; Cochet, C. Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol. 2002, 12, 226-230.
4. Tawfic, S.; Yu, S.; Wang, H.; Faust, R.; Davis, A.; Ahmed, K. Protein kinase CK2 signal in neoplasia. Histol. Histopathol. 2001, 16, 573-582.
5. Guerra, B.; Issinger, O. G. Protein kinase CK2 and its role in cellular proliferation, development and pathology. Electrophoresis 1999, 20, 391-408.
6. Seldin, D. C.; Leder, P. Casein kinase 2α-induced murine lymphoma: relation to Teilleriosis in cattle. Science. 1995, 267, 894-897.
7. Sarno, S.; Moro, S.; Meggio, F.; Zagotto, G.; Dal Ben, D.; Ghisellini, P.; Battistutta, R.; Zanotti, G.; Pinna, L. A. Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacol. Ther. 2002, 93, 159-168.
8. Battistutta, R.; De Moliner, E.; Sarno, S.; Zanotti, G.; Pinna, L. A. Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole. Protein Sci. 2001, 10, 2200-2206.
9. Battistutta, R.; Sarno, S.; De Moliner, E.; Papinutto, E.; Zanotti, G.; Pinna, L. A. The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J. Biol. Chem. 2000, 275, 29618-29622.
10. De Moliner, E.; Moro, S.; Sarno, S.; Zagotto, G.; Zanotti, G.; Pinna, L. A.; Battistutta, R. Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight. J. Biol. Chem. 2003, 278, 1831-1836.
11. Sarno, S.; Reddy, H.; Meggio, F.; Ruzzene, M.; Davies, S. P.; Donella-Deana, A.; Shugar, D.; Pinna, L. A. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Lett. 2001, 496, 44-48.
12. Ruzzene, M.; Penzo, D.; Pinna, L. A. Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem. J. 2002, 364, 41-47.
13. Shoichet, B. K.; McGovern, S. L.; Wei, B.; Irwin, J. J. Lead discovery using molecular docking. Curr. Opin. Chem. Biol. 2002, 6, 439-446.
14. Schneider, G.; Böhm, H.-J. Virtual screening and fast automated docking methods. Drug Discov. Today 2002, 7, 64-70.
15. Niefind, K.; Guerra, B.; Ermakowa, I.; Issinger, O. G. Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme. EMBO J. 2001, 20, 5320-5331.
16. Kuntz, I. D.; Meng, E. C.; Shoichet, B. K. Structure-based molecular design [Review]. Acc. Chem. Res. 1994, 27, 117-123.
17. Filikov, A. V.; James, T. L. Structure-based design of ligands for protein basic domains: application to the HIV-1 Tat protein. J. Comput.-Aided Mol. Des. 1998, 12, 229-240.
18. Shoichet, B. K.; Stroud, R. M.; Santi, D. V.; Kuntz, I. D.; Perry, K. M. Structure-based discovery of inhibitors of thymidylate synthase. Science 1993, 259, 1445-1450.
19. Bodian, D. L.; Yamasaki, R. B.; Buswell, R. L.; Stearns, J. F.; White, J. M.; Kuntz, I. D. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry 1993, 32, 2967-2978.
20. Ring, C. S.; Sun, E.; McKerrow, J. H.; Lee, G. K.; Rosenthal, P. J.; Kuntz, I. D.; Cohen, F. E. Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc. Natl. Acad. Sci. 1993, 90, 3583-3587.
21. Boehm, H.-J.; Stahl, M. The use of scoring functions in drug discovery applications. In Reviews in Computational Chemistry; Lipkowitz K. B., Boyd, D. B., Eds.; Wiley-VCH: New York, 2002; Vol. 18, pp 41-87.
22. Toledo, L. M.; Lydon, N. B.; Elbaum, D. The Structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem. 1999, 6, 775-805.
23. Traxler, P.; Furet, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Ther. 1999, 82, 195-206.
24. Furet, P.; Meyer, T.; Strauss, A.; Raccuglia, S.; Rondeau, J. M. Structure-based design and protein X-ray analysis of a protein kinase inhibitor. Bioorg. Med. Chem. Lett. 2002, 12, 221-224.
25. Wang, R.; Liu, L.; Lai, L.; Tang, Y. SCORE: A New Empirical Method for Structure-Based Estimation of Binding Affinities. J. Mol. Model. 1998, 4, 379-394.
26. Moore, J. A.; Sutherland, G. J.; Sowerby, R.; Kelly, E. G.; Palermo, S.; Webster, W. Reactions of anthranilamide and o-aminoacetophenone with benzil and benzoin. J. Org. Chem. 1969, 34, 887-892.
27. Moehrle, H.; Seidel, Ch. M. Quinolinones as starting products for pentacyclic heterocycles. Arch. Pharm. (Weinheim, Ger.) 1974, 307, 785-791.
28. described in lit.: Zimmermann, K.; Portmann, R.; Rigel, D. F. Preparation of indoloquinazolinones as PARP inhibitors. PCT Int. Appl. WO 0206284 A1, 2001.
29. United Devices, Austin, TX (see website: http://www.ud.com).
30. Bairoch, A.; Boeckmann, B. The SWISS-PROT protein sequence data bank: current status. Nucleic Acids Res. 1994, 22, 3578- 3580.
31. Bernstein, F. C.; Koetzle, T. F.; Williams, G. J. B.; Meyer, E. F.; Brice, M. D.; Rodgers, J. R.; Kennard, O.; Shimanouchi, T.; Tasumi, M. The Protein Data Bank: a Computer-based Archival File for Macromolecular Structures. J. Mol. Biol. 1977, 112, 535-542.
32. Niefind, K.; Putter, M.; Guerra, B.; Issinger, O. G.; Schomburg, D. GTP plus water mimic ATP in the active site of protein kinase CK2. Nat. Struct. Biol. 1999, 12, 1100-1103.
33. Insight II, Accelrys, San Diego, CA.
34. Vriend, G.; WHAT IF: A molecular modeling and drug design program. J. Mol. Graph. 1990, 8, 52-56.
35. Tripos Inc. Sybyl 6.6. St. Louis MO, 2001.
36. Gasteiger, J.; Rudolph, C.; Sadowski, J. Automatic generation of 3D atomic coordinates for organic molecules. Tetrahedron Comput. Methodol. 1990, 3, 537-547.
37. Gasteiger, J.; Marsili, M. Iterative Partial Equalization of Orbital Electronegativity - A Rapid Access to Atomic Charges. Tetrahedron 1980, 36, 3219-3228.
38. Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R. T.; Ferrin, T. E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 1982, 161, 269-288.
39. Ewing, T. J. A.; Kuntz, I. D. Critical evaluation of search algorithms for automated molecular docking and database screening. J. Comput. Chem. 1997, 18, 1175-1189.
40. described in lit.: Citterio, A.; Breviglieri, G.; Bruno, G. Eur. Pat. Appl. (2001), EP 1127877. A2 and Aufderhaar, E. Eur. Pat. Appl. EP 28028, 1981.
41. described in lit.: Citterio, A.; Breviglieri, G.; Bruno, G. Eur. Pat. Appl. (2001), EP 1127877. A2 and Aufderhaar, E. Eur. Pat. Appl. EP 28028, 1981.
42. Meggio, F.; Donella Deana, A.; Ruzzene, M.; Brunati, A. M.; Cesaro, L.; Guerra, B.; Meyer, T.; Mett, H.; Fabbro, D.; Furet, P.; Dobrowolska, G.; Pinna, L. A. Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur. J. Biochem. 1995, 234, 317-322.
43. Rialet, V.; Meijer, L. A New Screening Test for Antimitotic compounds affinity-immobilized on p13suc1 -coated microtitration plates. Anticancer Res. 1991, 11, 1581-1590.
44. Meyer, T.; Regenass, U.; Fabbro, D.; Alteri, E.; Roesel, J.; Muller, M.; Caravatti, G.; Matter, A. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo antitumor activity. Int. J. Cancer 1989, 43, 851-856.